Key result
Tolvaptan triggers V1 receptor-mediated aldosterone production, potentially explaining its neutral outcomes in EVEREST.
Key points are not available for this paper at this time.
Peer Reviewed
No takes yet. Share an insight, caveat, or question.
Pitt et al. (2011) studied this question. Selective V2 receptor antagonism with tolvaptan causes V1 receptor-mediated aldosterone production, potentially explaining its failure to reduce cardiovascular outcomes in the EVEREST trial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: